GSK settles another lawsuit over cancer relating to heartburn drug
Zantac became the world’s best-selling medicine in 1988 and one of the first to top $1bn in annual sales
29 July 2024 - 10:54
byYadarisa Shabong and Shanima A
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
UK drugmaker GSK said on Monday it had agreed to confidentially settle a lawsuit in Illinois that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.
First approved in 1983, Zantac, sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim, became the world’s best-selling medicine in 1988 and one of the first to top $1bn in annual sales.
The companies together are facing thousands of petitions against them including more than 70,000 lawsuits in Delaware.
Lawsuits began piling up after the US Food and Drug Administration in 2020 asked manufacturers to pull the drug off the market over concerns that ranitidine, an active ingredient in the drug, could degrade into a cancer-causing chemical over time or when exposed to heat.
GSK did not admit any liability and said it would vigorously defend itself in any other Zantac cases.
The company’s shares were up 0.8% in early trade on Monday.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
GSK settles another lawsuit over cancer relating to heartburn drug
Zantac became the world’s best-selling medicine in 1988 and one of the first to top $1bn in annual sales
UK drugmaker GSK said on Monday it had agreed to confidentially settle a lawsuit in Illinois that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.
First approved in 1983, Zantac, sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim, became the world’s best-selling medicine in 1988 and one of the first to top $1bn in annual sales.
The companies together are facing thousands of petitions against them including more than 70,000 lawsuits in Delaware.
Lawsuits began piling up after the US Food and Drug Administration in 2020 asked manufacturers to pull the drug off the market over concerns that ranitidine, an active ingredient in the drug, could degrade into a cancer-causing chemical over time or when exposed to heat.
GSK did not admit any liability and said it would vigorously defend itself in any other Zantac cases.
The company’s shares were up 0.8% in early trade on Monday.
Reuters
Novo Nordisk and Indonesia’s Bio Farma sign deal to produce insulin
Small private hospital groups get competition lifeline
Life Healthcare seals deal to sub-license cancer-screening tool
WATCH: Behind Aspen’s push for vaccine autonomy in Africa
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Novo Nordisk and Indonesia’s Bio Farma sign deal to produce insulin
Small private hospital groups get competition lifeline
Life Healthcare seals deal to sub-license cancer-screening tool
WATCH: Behind Aspen’s push for vaccine autonomy in Africa
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.